{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:30:19Z","timestamp":1793320219199,"version":"4.5.0"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41433-025-03845-8","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T13:08:05Z","timestamp":1747919285000},"page":"1901-1932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative efficacy and safety of rituximab, tocilizumab, and teprotumumab in Graves\u2019 orbitopathy: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6264-3763","authenticated-orcid":false,"given":"Abdulelah G.","family":"Abumohssin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan A.","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saja","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alqutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulsalam","family":"Alqutub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"3845_CR1","first-page":"78","volume":"28","author":"S Klet","year":"2023","unstructured":"Klet S, Markovi\u0107 B, Jani\u0107 T, Stojkovi\u0107 M, \u0106iri\u0107 J, Beleslin BN, et al. Steroid-resistant Graves\u2019orbitopathy\u2013therapeutic options. Med Glas Spec Boln za Boles \u0161titaste \u017elezde Boles Metab. 2023;28:78\u201390.","journal-title":"Med Glas Spec Boln za Boles \u0161titaste \u017elezde Boles Metab"},{"key":"3845_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1297658","volume":"2017","author":"M Ventura","year":"2017","unstructured":"Ventura M, Melo M, Carrilho F. Selenium and thyroid disease: from pathophysiology to treatment. Int J Endocrinol. 2017;2017:1297658. https:\/\/doi.org\/10.1155\/2017\/1297658.","journal-title":"Int J Endocrinol"},{"key":"3845_CR3","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3390\/medicina58121748","volume":"58","author":"C Lu","year":"2022","unstructured":"Lu C, Lai CL, Yang CM, Liao KC, Kao CS, Chang TC, et al. The relationship between obesity-related factors and Graves\u2019 orbitopathy: a pilot study. Medicine. 2022;58:1748 https:\/\/doi.org\/10.3390\/medicina58121748.","journal-title":"Medicine"},{"key":"3845_CR4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45907","volume":"15","author":"P Gupta","year":"2023","unstructured":"Gupta P, Kaur N, Goyal A, Aggarwal A. Atypical asymmetric presentation of severe Graves\u2019 orbitopathy. Cureus. 2023;15:e45907. https:\/\/doi.org\/10.7759\/cureus.45907.","journal-title":"Cureus"},{"key":"3845_CR5","doi-asserted-by":"crossref","unstructured":"Buldygina YV, Terekhova GM, Strafun LS, Savosko II, Lysova ZG, Shlyakhtych SL. Assessing the efficacy of various treatment regimens for patients with endocrine ophthalmopathy associated with Graves\u2019 disease. J Ophthalmol. 2022;96:311\u201328.","DOI":"10.31288\/oftalmolzh202215157"},{"key":"3845_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-018-2876-0","volume":"19","author":"L Brammen","year":"2018","unstructured":"Brammen L, Riss P, Lukas J, Gessl A, Dunkler D, Li S, et al. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves\u2019 ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial. Trials. 2018;19:495. https:\/\/doi.org\/10.1186\/s13063-018-2876-0.","journal-title":"Trials"},{"key":"3845_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/vim.2016.0043","volume":"29","author":"K Kumata","year":"2016","unstructured":"Kumata K, Nagata K, Matsushita M, Kuwamoto S, Kato M, Murakami I, et al. Thyrotropin Receptor Antibody (TRAb)-IgM levels are markedly higher than TRAb-IgG levels in Graves\u2019 disease patients and controls, and TRAb-IgM production is related to Epstein-Barr virus reactivation. Viral Immunol. 2016;29:459\u201363. https:\/\/doi.org\/10.1089\/vim.2016.0043.","journal-title":"Viral Immunol"},{"key":"3845_CR8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3803\/EnM.2016.31.2.300","volume":"31","author":"H Kwon","year":"2016","unstructured":"Kwon H, Kim WG, Jang EK, Kim M, Park S, Jeon MJ, et al. Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease. Endocrinol Metab. 2016;31:300\u201310. https:\/\/doi.org\/10.3803\/EnM.2016.31.2.300.","journal-title":"Endocrinol Metab"},{"key":"3845_CR9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.52260","volume":"16","author":"LP Menon","year":"2024","unstructured":"Menon LP, Naqvi S, Maradana J, Edem D. Recurrent Graves\u2019 disease following near-total thyroidectomy: a case report and literature review. Cureus. 2024;16:e52260. https:\/\/doi.org\/10.7759\/cureus.52260.","journal-title":"Cureus"},{"key":"3845_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1153312","volume":"14","author":"J Park","year":"2023","unstructured":"Park J, Kim J, Kim SS, Choi HY. Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe Graves\u2019 orbitopathy. Front Endocrinol. 2023;14:1153312. https:\/\/doi.org\/10.3389\/fendo.2023.1153312.","journal-title":"Front Endocrinol"},{"key":"3845_CR11","first-page":"89","volume":"3","author":"M Ujianto","year":"2024","unstructured":"Ujianto M, Sari F, Rakhman MF. Unveiling modern strategies for diagnosing and treating grave orbitopathy. J Klin dan Ris Kesehat. 2024;3:89\u2013106.","journal-title":"J Klin dan Ris Kesehat"},{"key":"3845_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","volume":"16","author":"PN Taylor","year":"2020","unstructured":"Taylor PN, Zhang L, Lee RWJ, Muller I, Ezra DG, Dayan CM, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16:104\u201316. https:\/\/doi.org\/10.1038\/s41574-019-0305-4.","journal-title":"Nat Rev Endocrinol"},{"key":"3845_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jum.15401","volume":"40","author":"D Walasik-Szempli\u0144ska","year":"2021","unstructured":"Walasik-Szempli\u0144ska D, Kami\u0144ski G, Sudo\u0142-Szopi\u0144ska I. Impact of radioiodine treatment on doppler flow parameters in the central retinal artery and ophthalmic artery in patients with hyperthyroidism. J Ultrasound Med. 2021;40:305\u201318. https:\/\/doi.org\/10.1002\/jum.15401.","journal-title":"J Ultrasound Med"},{"key":"3845_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1167\/iovs.64.11.13","volume":"64","author":"HJ Byeon","year":"2023","unstructured":"Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, et al. The role of adipsin, complement factor D, in the pathogenesis of Graves\u2019 orbitopathy. Invest Ophthalmol Vis Sci. 2023;64:13 https:\/\/doi.org\/10.1167\/iovs.64.11.13.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3845_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40618-015-0322-7","volume":"39","author":"M Nowak","year":"2016","unstructured":"Nowak M, Siemi\u0144ska L, Karpe J, Marek B, Kos-Kud\u0142a B, Kajdaniuk D. Serum concentrations of HGF and IL-8 in patients with active Graves\u2019 orbitopathy before and after methylprednisolone therapy. J Endocrinol Investig. 2016;39:63\u201372. https:\/\/doi.org\/10.1007\/s40618-015-0322-7.","journal-title":"J Endocrinol Investig"},{"key":"3845_CR16","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/lary.21392","volume":"121","author":"ZM Soler","year":"2011","unstructured":"Soler ZM, Platt MP, Leung MK, Mong S, Metson R. Sinonasal abnormalities in patients with Graves\u2019 orbitopathy. Laryngoscope. 2011;121:656\u201360. https:\/\/doi.org\/10.1002\/lary.21392.","journal-title":"Laryngoscope"},{"key":"3845_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1055\/s-0029-1243057","volume":"134","author":"KA Ponto","year":"2009","unstructured":"Ponto KA, Pitz S, Mann WJ, Weber MM, Pfeiffer N, Kahaly GJ. Vorgehen bei endokriner Orbitopathie. Evidenzbasierte Empfehlungen [Management of Graves\u2019 orbitopathy: evidence-based recommendations]. Dtsch Med Wochenschr. 2009;134:2521\u20134. https:\/\/doi.org\/10.1055\/s-0029-1243057.","journal-title":"Dtsch Med Wochenschr"},{"key":"3845_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5348\/crint-2017-36-CR-5","volume":"6","author":"P Devarbhavi","year":"2017","unstructured":"Devarbhavi P, Maiti A, Sinha A, Basu A, Chakraborty S, Dey L, et al. Rituximab therapy in steroid resistant thyroid associated ophthalmopathy. Case Rep Int. 2017;6:1\u20134. https:\/\/doi.org\/10.5348\/crint-2017-36-CR-5.","journal-title":"Case Rep Int"},{"key":"3845_CR19","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","volume":"38","author":"E Sisti","year":"2015","unstructured":"Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, et al. Long-term outcome of Graves\u2019 orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Investig. 2015;38:661\u20138. https:\/\/doi.org\/10.1007\/s40618-015-0241-7.","journal-title":"J Endocrinol Investig"},{"key":"3845_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","volume":"26","author":"A Eckstein","year":"2012","unstructured":"Eckstein A, Schittkowski M, Esser J. Surgical treatment of Graves\u2019 ophthalmopathy. Best Pr Res Clin Endocrinol Metab. 2012;26:339\u201358. https:\/\/doi.org\/10.1016\/j.beem.2011.11.002.","journal-title":"Best Pr Res Clin Endocrinol Metab"},{"key":"3845_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1590\/s0004-27492012000200012","volume":"75","author":"F Eing","year":"2012","unstructured":"Eing F, Cruz AA. Surgical treatment of globe subluxation in the active phase of the myogenic type of Graves orbitopathy: case reports. Arq Bras Oftalmol. 2012;75:131\u20133. https:\/\/doi.org\/10.1590\/s0004-27492012000200012.","journal-title":"Arq Bras Oftalmol"},{"key":"3845_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1055\/s-0035-1554721","volume":"47","author":"M Salvi","year":"2015","unstructured":"Salvi M, Campi I. Medical Treatment of Graves\u2019 Orbitopathy. Horm Metab Res. 2015;47:779\u201388. https:\/\/doi.org\/10.1055\/s-0035-1554721.","journal-title":"Horm Metab Res"},{"key":"3845_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/phar.2111","volume":"38","author":"WC Shen","year":"2018","unstructured":"Shen WC, Lee CH, Loh EW, Hsieh AT, Chen L, Tam KW. Efficacy and safety of rituximab for the treatment of Graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials. Pharmacotherapy. 2018;38:503\u201310. https:\/\/doi.org\/10.1002\/phar.2111.","journal-title":"Pharmacotherapy"},{"key":"3845_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000536618","volume":"14","author":"G Oakman","year":"2024","unstructured":"Oakman G, Ong C. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis with overlap IgA nephropathy: a case report. Case Rep Nephrol Dial. 2024;14:36\u201341. https:\/\/doi.org\/10.1159\/000536618.","journal-title":"Case Rep Nephrol Dial"},{"key":"3845_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/IOP.0000000000002573","volume":"40","author":"AF Duarte","year":"2024","unstructured":"Duarte AF, Xavier NF, Sales Sanz M, Cruz AAV. Efficiency and safety of tocilizumab for the treatment of thyroid eye disease: a systematic review. Ophthalmic Plast Reconstr Surg. 2024;40:367\u201373. https:\/\/doi.org\/10.1097\/IOP.0000000000002573.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR26","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.3390\/jcm9092816","volume":"9","author":"L S\u00e1nchez-Bilbao","year":"2020","unstructured":"S\u00e1nchez-Bilbao L, Mart\u00ednez-L\u00f3pez D, Revenga M, L\u00f3pez-V\u00e1zquez \u00c1, Valls-Pascual E, Atienza-Mateo B, et al. Anti-IL-6 Receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients. J Clin Med. 2020;9:2816 https:\/\/doi.org\/10.3390\/jcm9092816.","journal-title":"J Clin Med"},{"key":"3845_CR27","doi-asserted-by":"publisher","first-page":"e220185","DOI":"10.1530\/ETJ-22-0185","volume":"11","author":"L Bartalena","year":"2022","unstructured":"Bartalena L. Role of teprotumumab in the treatment of active moderate-to-severe Graves\u2019 orbitopathy. Eur Thyroid J. 2022;11:e220185 https:\/\/doi.org\/10.1530\/ETJ-22-0185.","journal-title":"Eur Thyroid J"},{"key":"3845_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6638089","volume":"2023","author":"F Lin","year":"2023","unstructured":"Lin F, Yao Q, Yu B, Deng Z, Qiu J, He R. The efficacy and safety of teprotumumab in thyroid eye disease: evidence from randomized controlled trials. Int J Clin Pr. 2023;2023:6638089. https:\/\/doi.org\/10.1155\/2023\/6638089.","journal-title":"Int J Clin Pr"},{"key":"3845_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/IOP.0000000000002315","volume":"39","author":"NF Xavier","year":"2023","unstructured":"Xavier NF, Lucena DT, Cruz AAV. Monoclonal antibodies for the treatment of graves orbitopathy: precision medicine?. Ophthalmic Plast Reconstr Surg. 2023;39:307\u201315. https:\/\/doi.org\/10.1097\/IOP.0000000000002315.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4103\/sjopt.sjopt_176_22","volume":"37","author":"WA Fatani","year":"2023","unstructured":"Fatani WA, Hamdan DM, Taher NO, Alsharef JF, Aldubi RM, Alwagdani AM, et al. Monoclonal antibodies for the treatment of Graves\u2019 ophthalmopathy: a systematic review and meta-analysis. Saudi J Ophthalmol. 2023;37:137\u201348. https:\/\/doi.org\/10.4103\/sjopt.sjopt_176_22.","journal-title":"Saudi J Ophthalmol"},{"key":"3845_CR31","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"3845_CR32","doi-asserted-by":"crossref","unstructured":"Higgins JP: Cochrane handbook for systematic reviews of interventions version 5.0.1. The Cochrane Collaboration. http:\/\/www.cochrane-handbook.org 2008.","DOI":"10.1002\/9780470712184"},{"key":"3845_CR33","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11547-020-01244-5","volume":"126","author":"PP Limone","year":"2021","unstructured":"Limone PP, Bianco L, Mellano M, Garino F, Giannoccaro F, Rossi A, et al. Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy?. Radio Med. 2021;126:334\u201342. https:\/\/doi.org\/10.1007\/s11547-020-01244-5.","journal-title":"Radio Med"},{"key":"3845_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol. 1997;47:9\u201314. https:\/\/doi.org\/10.1046\/j.1365-2265.1997.2331047.x.","journal-title":"Clin Endocrinol"},{"key":"3845_CR35","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2147\/OPTH.S305717","volume":"15","author":"N Quah Qin Xian","year":"2021","unstructured":"Quah Qin Xian N, Alnahrawy A, Akshikar R, Lee V. Real-world efficacy and safety of mycophenolate mofetil in active moderate-to-sight-threatening thyroid eye disease. Clin Ophthalmol. 2021;15:1921\u201332. https:\/\/doi.org\/10.2147\/OPTH.S305717.","journal-title":"Clin Ophthalmol"},{"key":"3845_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9879503","volume":"2021","author":"SX Fan","year":"2021","unstructured":"Fan SX, Zeng P, Li ZJ, Wang J, Liang JQ, Liao YR, et al. The clinical features of Graves\u2019 orbitopathy with elevated intraocular pressure. J Ophthalmol. 2021;2021:9879503. https:\/\/doi.org\/10.1155\/2021\/9879503.","journal-title":"J Ophthalmol"},{"key":"3845_CR37","unstructured":"Quality assessment tool for observational cohort and cross-sectional studies [https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools]."},{"key":"3845_CR38","unstructured":"Health NIo: Quality assessment tool for case series studies. NHLBI NIH.gov Web site[Accessed September 24, 2020] 2017."},{"key":"3845_CR39","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928 https:\/\/doi.org\/10.1136\/bmj.d5928.","journal-title":"BMJ"},{"key":"3845_CR40","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919 https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"3845_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4103\/tjo.tjo_30_22","volume":"12","author":"MO Adetunji","year":"2022","unstructured":"Adetunji MO, Nguyen BJ, McGeehan B, Tamhankar MA, Brice\u00f1o CA. Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. Taiwan J Ophthalmol. 2022;12:325\u20139. https:\/\/doi.org\/10.4103\/tjo.tjo_30_22.","journal-title":"Taiwan J Ophthalmol"},{"key":"3845_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/IOP.0000000000002707","volume":"41","author":"EM Al-Sharif","year":"2025","unstructured":"Al-Sharif EM, Zhou J, Shoji MK, Acuff K, Liu CY, Korn BS, et al. Effects of teprotumumab on eyelid retraction in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2025;41:22\u201327. https:\/\/doi.org\/10.1097\/IOP.0000000000002707.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR43","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1210\/clinem\/dgac627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"Amarikwa L, Mohamed A, Kim SH, Kossler AL, Dosiou C. Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab. 2023;108:858\u201364. https:\/\/doi.org\/10.1210\/clinem\/dgac627.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR44","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1080\/09273948.2020.1808688","volume":"30","author":"A Bennedja\u00ef","year":"2022","unstructured":"Bennedja\u00ef A, Bouheraoua N, Gatfoss\u00e9 M, Dupasquier-Fediaevsky L, Errera MH, Tazartes M, et al. Tocilizumab versus rituximab in patients with moderate to severe steroid-resistant Graves\u2019 orbitopathy. Ocul Immunol Inflamm. 2022;30:500\u20135. https:\/\/doi.org\/10.1080\/09273948.2020.1808688.","journal-title":"Ocul Immunol Inflamm"},{"key":"3845_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1186105","volume":"14","author":"G Boutzios","year":"2023","unstructured":"Boutzios G, Chatzi S, Goules AV, Mina A, Charonis GC, Vlachoyiannopoulos PG, et al. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves\u2019 orbitopathy: an observational study. Front Endocrinol. 2023;14:1186105. https:\/\/doi.org\/10.3389\/fendo.2023.1186105.","journal-title":"Front Endocrinol"},{"key":"3845_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.790246","volume":"12","author":"I Campi","year":"2022","unstructured":"Campi I, Vannucchi G, Muller I, Lazzaroni E, Curr\u00f2 N, Dainese M, et al. Therapy with different dose regimens of rituximab in patients with active moderate-to-severe Graves\u2019 orbitopathy. Front Endocrinol. 2022;12:790246. https:\/\/doi.org\/10.3389\/fendo.2021.790246.","journal-title":"Front Endocrinol"},{"key":"3845_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ando.2020.01.003","volume":"81","author":"J Ceballos-Mac\u00edas Jos\u00e9","year":"2020","unstructured":"Ceballos-Mac\u00edas Jos\u00e9 J, Rivera-Moscoso R, Flores-Real Jorge A, Vargas-S\u00e1nchez J, Ortega-Guti\u00e9rrez G, Madriz-Prado R, et al. Tocilizumab in glucocorticoid-resistant Graves orbitopathy. A case series report of a Mexican population. Ann Endocrinol. 2020;81:78\u201382. https:\/\/doi.org\/10.1016\/j.ando.2020.01.003.","journal-title":"Ann Endocrinol"},{"key":"3845_CR48","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/IOP.0000000000002611","volume":"40","author":"LO Dallalzadeh","year":"2024","unstructured":"Dallalzadeh LO, Villatoro GA, Chen L, Sim MS, Movaghar M, Robbins SL, et al. Teprotumumab for thyroid eye disease-related strabismus. Ophthalmic Plast Reconstr Surg. 2024;40:434\u20139. https:\/\/doi.org\/10.1097\/IOP.0000000000002611.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR49","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/WNO.0000000000002066","volume":"44","author":"JB Davis","year":"2024","unstructured":"Davis JB, Mudalegundi S, Henderson AD, Carey AR. Stability of ocular alignment after teprotumumab therapy in a cohort of patients with thyroid eye disease and baseline diplopia. J Neuroophthalmol. 2024;44:527\u201332. https:\/\/doi.org\/10.1097\/WNO.0000000000002066.","journal-title":"J Neuroophthalmol"},{"key":"3845_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.oftal.2018.04.011","volume":"93","author":"L de-Pablo-G\u00f3mez-de-Lia\u00f1o","year":"2018","unstructured":"de-Pablo-G\u00f3mez-de-Lia\u00f1o L, Fern\u00e1ndez-Vigo JI, Troyano-Rivas J, Ni\u00f1o-Rueda C, Romo-L\u00f3pez \u00c1, G\u00f3mez-de-Lia\u00f1o R. Response to tocilizumab treatment in Graves\u2019 ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography. Arch Soc Esp Oftalmol. 2018;93:386\u201391. https:\/\/doi.org\/10.1016\/j.oftal.2018.04.011.","journal-title":"Arch Soc Esp Oftalmol"},{"key":"3845_CR51","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00417-020-04651-6","volume":"258","author":"JB Deltour","year":"2020","unstructured":"Deltour JB, d\u2019Assigny Flamen M, Ladsous M, Giovansili L, Cariou B, Caron P, et al. Efficacy of rituximab in patients with Graves\u2019 orbitopathy: a retrospective multicenter nationwide study. Graefes Arch Clin Exp Ophthalmol. 2020;258:2013\u201321. https:\/\/doi.org\/10.1007\/s00417-020-04651-6.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3845_CR52","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","volume":"37","author":"SB Diniz","year":"2021","unstructured":"Diniz SB, Cohen LM, Roelofs KA, Rootman DB. Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population. Ophthalmic Plast Reconstr Surg. 2021;37:583\u201391. https:\/\/doi.org\/10.1097\/IOP.0000000000001959.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR53","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/01676830.2022.2119262","volume":"42","author":"O Dorado Cortez","year":"2023","unstructured":"Dorado Cortez O, Grivet D, Perrillat N, Gain P, Thuret G. Treatment of corticosteroid-resistant Graves\u2019 orbitopathy with tocilizumab: a single-centre prospective study. Orbit. 2023;42:411\u20137. https:\/\/doi.org\/10.1080\/01676830.2022.2119262.","journal-title":"Orbit"},{"key":"3845_CR54","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian ps, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109:25\u201335. https:\/\/doi.org\/10.1210\/clinem\/dgad637.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR55","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020;382:341\u201352. https:\/\/doi.org\/10.1056\/NEJMoa1910434.","journal-title":"N Engl J Med"},{"key":"3845_CR56","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S, Elflein H, Ponto KA, Fowler BT, et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology. 2022;129:438\u201349. https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017.","journal-title":"Ophthalmology"},{"key":"3845_CR57","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/09273948.2018.1453078","volume":"27","author":"L Du Pasquier-Fediaevsky","year":"2019","unstructured":"Du Pasquier-Fediaevsky L, Andrei S, Berche M, Leenhardt L, H\u00e9ron E, Rivi\u00e8re S. Low-dose rituximab for active moderate to severe graves\u2019 orbitopathy resistant to conventional treatment. Ocul Immunol Inflamm. 2019;27:844\u201350. https:\/\/doi.org\/10.1080\/09273948.2018.1453078.","journal-title":"Ocul Immunol Inflamm"},{"key":"3845_CR58","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1177\/1120672119845224","volume":"30","author":"L Eid","year":"2020","unstructured":"Eid L, Coste-Verdier V, Longueville E, Ribeiro E, Nicolescu-Catargi B, Korobelnik JF. The effects of Rituximab on Graves\u2019orbitopathy: a retrospective study of 14 patients. Eur J Ophthalmol. 2020;30:1008\u201313. https:\/\/doi.org\/10.1177\/1120672119845224.","journal-title":"Eur J Ophthalmol"},{"key":"3845_CR59","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","volume":"92","author":"D El Fassi","year":"2007","unstructured":"El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Heged\u00fcs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. J Clin Endocrinol Metab. 2007;92:1769\u201372. https:\/\/doi.org\/10.1210\/jc.2006-2388.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR60","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3109\/08916934.2014.939266","volume":"47","author":"A Erdei","year":"2014","unstructured":"Erdei A, Paragh G, Kovacs P, Karanyi Z, Berenyi E, Galuska L, et al. Rapid response to and long-term effectiveness of anti-CD20 antibody in conventional therapy resistant Graves\u2019 orbitopathy: a five-year follow-up study. Autoimmunity. 2014;47:548\u201355. https:\/\/doi.org\/10.3109\/08916934.2014.939266.","journal-title":"Autoimmunity"},{"key":"3845_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10792-024-03143-4","volume":"44","author":"FA Habroosh","year":"2024","unstructured":"Habroosh FA, Albrashdi SS, Alsaadi AH, Eatamadi H. Tocilizumab use for optic nerve compression in thyroid eye disease: a prospective longitudinal cohort. Int Ophthalmol. 2024;44:222 https:\/\/doi.org\/10.1007\/s10792-024-03143-4.","journal-title":"Int Ophthalmol"},{"key":"3845_CR62","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-08-0084","volume":"159","author":"KA Heemstra","year":"2008","unstructured":"Heemstra KA, Toes RE, Sepers J, Pereira AM, Corssmit EP, Huizinga TW, et al. Rituximab in relapsing Graves\u2019 disease, a phase II study. Eur J Endocrinol. 2008;159:609\u201315. https:\/\/doi.org\/10.1530\/EJE-08-0084.","journal-title":"Eur J Endocrinol"},{"key":"3845_CR63","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ajo.2024.01.005","volume":"262","author":"G Hilliard","year":"2024","unstructured":"Hilliard G, Pruett J, Donahue SP, Velez FG, Peragallo JH, Ditta LC, et al. Outcomes of strabismus surgery following teprotumumab therapy. Am J Ophthalmol. 2024;262:186\u201391. https:\/\/doi.org\/10.1016\/j.ajo.2024.01.005.","journal-title":"Am J Ophthalmol"},{"key":"3845_CR64","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/IOP.0000000000002267","volume":"39","author":"TC Ho","year":"2023","unstructured":"Ho TC, Maamari RN, Kossler AL, Sears CM, Freitag SK, Reshef ER, et al. Outcomes of patients with thyroid eye disease partially treated with teprotumumab. Ophthalmic Plast Reconstr Surg. 2023;39:150\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000002267.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR65","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/clinem\/dgae417","volume":"110","author":"J Huang","year":"2024","unstructured":"Huang J, Su A, Yang J, Zhuang W, Li Z Sr. Postmarketing safety concerns of teprotumumab: a real-world pharmacovigilance assessment. J Clin Endocrinol Metab. 2024;110:159\u201365. https:\/\/doi.org\/10.1210\/clinem\/dgae417.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR66","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/IOP.0000000000002563","volume":"40","author":"S Hubschman","year":"2024","unstructured":"Hubschman S, Sojitra B, Ghiam S, Sears C, Hwangbo N, Goldberg RA, et al. Teprotumumab and orbital decompression for the management of proptosis in patients with thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2024;40:270\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000002563.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR67","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajo.2023.12.001","volume":"263","author":"CJ Hwang","year":"2024","unstructured":"Hwang CJ, Rebollo NP, Mechels KB, Perry JD. Reactivation after teprotumumab treatment for active thyroid eye disease. Am J Ophthalmol. 2024;263:152\u20139. https:\/\/doi.org\/10.1016\/j.ajo.2023.12.001.","journal-title":"Am J Ophthalmol"},{"key":"3845_CR68","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cen.13970","volume":"91","author":"EA Insull","year":"2019","unstructured":"Insull EA, Sipkova Z, David J, Turner HE, Norris JH. Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment. Clin Endocrinol. 2019;91:179\u201386. https:\/\/doi.org\/10.1111\/cen.13970.","journal-title":"Clin Endocrinol"},{"key":"3845_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","volume":"106","author":"AP Jain","year":"2022","unstructured":"Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2022;106:165\u201371. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-317806.","journal-title":"Br J Ophthalmol"},{"key":"3845_CR70","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diab Endocrinol. 2021;9:360\u201372. https:\/\/doi.org\/10.1016\/S2213-8587(21)00056-5.","journal-title":"Lancet Diab Endocrinol"},{"key":"3845_CR71","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1089\/thy.2023.0656","volume":"34","author":"GJ Kahaly","year":"2024","unstructured":"Kahaly GJ, Subramanian PS, Conrad E, Holt RJ, Smith TJ. Long-term efficacy of teprotumumab in thyroid eye disease: follow-up outcomes in three clinical trials. Thyroid. 2024;34:880\u20139. https:\/\/doi.org\/10.1089\/thy.2023.0656.","journal-title":"Thyroid"},{"key":"3845_CR72","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5603\/EP.a2017.0040","volume":"68","author":"D Karasek","year":"2017","unstructured":"Karasek D, Cibickova L, Karhanova M, Kalitova J, Schovanek J, Frysak Z. Clinical and immunological changes in patients with active moderate-to-severe Graves\u2019 orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017;68:498\u2013504. https:\/\/doi.org\/10.5603\/EP.a2017.0040.","journal-title":"Endokrynol Pol"},{"key":"3845_CR73","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","volume":"131","author":"JA Keen","year":"2024","unstructured":"Keen JA, Correa T, Pham C, Claussen AD, Hansen MR, Carter KD, et al. Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology. 2024;131:30\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001.","journal-title":"Ophthalmology"},{"key":"3845_CR74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117:133\u2013139.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2009.05.029.","journal-title":"Ophthalmology"},{"key":"3845_CR75","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10792-024-03117-6","volume":"44","author":"C Lee","year":"2024","unstructured":"Lee C, Park JW, Kim YD, Woo KI. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study. Int Ophthalmol. 2024;44:179 https:\/\/doi.org\/10.1007\/s10792-024-03117-6.","journal-title":"Int Ophthalmol"},{"key":"3845_CR76","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000453618","volume":"99","author":"J Li","year":"2017","unstructured":"Li J, Xiao Z, Hu X, Li Y, Zhang X, Zhang S, et al. The Efficacy of Rituximab combined with 131I for ophthalmic outcomes of Graves\u2019 ophthalmopathy patients. Pharmacology. 2017;99:144\u201352. https:\/\/doi.org\/10.1159\/000453618.","journal-title":"Pharmacology"},{"key":"3845_CR77","doi-asserted-by":"publisher","first-page":"E1294","DOI":"10.1210\/jc.2013-3207","volume":"99","author":"AN McCoy","year":"2014","unstructured":"McCoy AN, Kim DS, Gillespie EF, Atkins SJ, Smith TJ, Douglas RS. Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells. J Clin Endocrinol Metab. 2014;99:E1294\u20139. https:\/\/doi.org\/10.1210\/jc.2013-3207.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR78","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cen.12141","volume":"79","author":"AL Mitchell","year":"2013","unstructured":"Mitchell AL, Gan EH, Morris M, Johnson K, Neoh C, Dickinson AJ, et al. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves\u2019 orbitopathy. Clin Endocrinol. 2013;79:437\u201342. https:\/\/doi.org\/10.1111\/cen.12141.","journal-title":"Clin Endocrinol"},{"key":"3845_CR79","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14655","volume":"97","author":"L Moi","year":"2022","unstructured":"Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves\u2019 orbitopathy treated with tocilizumab. Clin Endocrinol. 2022;97:363\u201370. https:\/\/doi.org\/10.1111\/cen.14655.","journal-title":"Clin Endocrinol"},{"key":"3845_CR80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.58585","volume":"16","author":"FA Mukit","year":"2024","unstructured":"Mukit FA, Manley A, Patel AB, Hashemi M, Laplant JF, Fleming JC, et al. Side effects and adverse events after treatment with teprotumumab for thyroid eye disease: a retrospective observational case series. Cureus. 2024;16:e58585. https:\/\/doi.org\/10.7759\/cureus.58585.","journal-title":"Cureus"},{"key":"3845_CR81","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1080\/01676830.2021.1933081","volume":"41","author":"DJ Ozzello","year":"2022","unstructured":"Ozzello DJ, Dallalzadeh LO, Liu CY. Teprotumumab for chronic thyroid eye disease. Orbit. 2022;41:539\u201346. https:\/\/doi.org\/10.1080\/01676830.2021.1933081.","journal-title":"Orbit"},{"key":"3845_CR82","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s00417-024-06491-0","volume":"262","author":"E Parunakian","year":"2024","unstructured":"Parunakian E, Ugradar S, Tolentino J, Malkhasyan E, Raika P, Ghaly J, et al. Teprotumumab improves light sensitivity in patients with thyroid eye disease. Graefes Arch Clin Exp Ophthalmol. 2024;262:2999\u20133006. https:\/\/doi.org\/10.1007\/s00417-024-06491-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3845_CR83","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, Perez-Pampin E, Romo Lopez A, Rodr\u00edguez Alvarez FM, et al. Tocilizumab in graves orbitopathy study group. efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195:181\u201390. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.038.","journal-title":"Am J Ophthalmol"},{"key":"3845_CR84","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/jcm10040706","volume":"10","author":"JV P\u00e9rez-Moreiras","year":"2021","unstructured":"P\u00e9rez-Moreiras JV, Varela-Agra M, Prada-S\u00e1nchez MC, Prada-Ramallal G. Steroid-resistant Graves\u2019 orbitopathy treated with tocilizumab in real-world clinical practice: a 9-year single-center experience. J Clin Med. 2021;10:706 https:\/\/doi.org\/10.3390\/jcm10040706.","journal-title":"J Clin Med"},{"key":"3845_CR85","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ando.2016.12.002","volume":"78","author":"F Pr\u00e9causta","year":"2017","unstructured":"Pr\u00e9causta F, Ars\u00e8ne S, Renoult-Pierre P, Laure B, Crini\u00e8re L, Pisella PJ. Treatment by rituximab on six Grave\u2019s ophthalmopathies resistant to corticosteroids. Ann Endocrinol. 2017;78:20\u201326. https:\/\/doi.org\/10.1016\/j.ando.2016.12.002.","journal-title":"Ann Endocrinol"},{"key":"3845_CR86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Dazzi D, Simonetta S, et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33\u201340. https:\/\/doi.org\/10.1530\/eje.1.02325.","journal-title":"Eur J Endocrinol"},{"key":"3845_CR87","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.clim.2008.12.005","volume":"131","author":"M Salvi","year":"2009","unstructured":"Salvi M, Vannucchi G, Campi I, Curr\u00f2 N, Simonetta S, Covelli D, et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol. 2009;131:360\u20135. https:\/\/doi.org\/10.1016\/j.clim.2008.12.005.","journal-title":"Clin Immunol"},{"key":"3845_CR88","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curr\u00f2 N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422\u201331. https:\/\/doi.org\/10.1210\/jc.2014-3014.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR89","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12020-014-0283-1","volume":"48","author":"G Savino","year":"2015","unstructured":"Savino G, Mandar\u00e0 E, Gari M, Battendieri R, Corsello SM, Pontecorvi A. Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy. Endocrine. 2015;48:241\u20137. https:\/\/doi.org\/10.1007\/s12020-014-0283-1.","journal-title":"Endocrine"},{"key":"3845_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101111","volume":"23","author":"CM Sears","year":"2021","unstructured":"Sears CM, Wang Y, Bailey LA, Turbin R, Subramanian PS, Douglas R, et al. Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: a multicenter study. Am J Ophthalmol Case Rep. 2021;23:101111. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101111.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3845_CR91","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/IOP.0b013e3181c4dfde","volume":"26","author":"RZ Silkiss","year":"2010","unstructured":"Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2010;26:310\u20134. https:\/\/doi.org\/10.1097\/IOP.0b013e3181c4dfde.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR92","doi-asserted-by":"publisher","first-page":"e4287","DOI":"10.1097\/GOX.0000000000004287","volume":"10","author":"BA Simmons","year":"2022","unstructured":"Simmons BA, Tran C, Pham CM, Shriver EM. The effect of teprotumumab on eyelid position in patients with thyroid eye disease. Plast Reconstr Surg Glob Open. 2022;10:e4287 https:\/\/doi.org\/10.1097\/GOX.0000000000004287.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"3845_CR93","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/IOP.0000000000002027","volume":"38","author":"LD Smith","year":"2022","unstructured":"Smith LD, Moscato EE, Seiff SR. Tocilizumab for the management of thyroid-associated orbitopathy. Ophthalmic Plast Reconstr Surg. 2022;38:188\u201392. https:\/\/doi.org\/10.1097\/IOP.0000000000002027.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR94","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.ophtha.2024.01.023","volume":"131","author":"TJ Smith","year":"2024","unstructured":"Smith TJ, Cavida D, Hsu K, Kim S, Fu Q, Barbesino G, et al. Glycemic trends in patients with thyroid eye disease treated with teprotumumab in 3 clinical trials. Ophthalmology. 2024;131:815\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.01.023.","journal-title":"Ophthalmology"},{"key":"3845_CR95","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.eprac.2024.02.002","volume":"30","author":"TJ Smith","year":"2024","unstructured":"Smith TJ, Cockerham K, Barretto N, Hirst A, Oliver L, Enstone A, et al. Bridging and validation of the specific graves ophthalmopathy quality of life questionnaire with health state utility values. Endocr Pr. 2024;30:470\u20135. https:\/\/doi.org\/10.1016\/j.eprac.2024.02.002.","journal-title":"Endocr Pr"},{"key":"3845_CR96","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1614949.","journal-title":"N Engl J Med"},{"key":"3845_CR97","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab. 2015;100:432\u201341. https:\/\/doi.org\/10.1210\/jc.2014-2572.","journal-title":"J Clin Endocrinol Metab"},{"key":"3845_CR98","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan MN, Salvi M. MAnagement of endocrine disease: rituximab therapy for Graves\u2019 orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176:R101\u2013R109. https:\/\/doi.org\/10.1530\/EJE-16-0552.","journal-title":"Eur J Endocrinol"},{"key":"3845_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/tjo.tjo_59_21","volume":"12","author":"SM Stevens","year":"2022","unstructured":"Stevens SM, Pirakitikulr N, Lee BW. Subcutaneous tocilizumab for active thyroid eye disease refractory to orbital radiation and systemic steroids in tobacco smokers. Taiwan J Ophthalmol. 2022;12:39\u201343. https:\/\/doi.org\/10.4103\/tjo.tjo_59_21.","journal-title":"Taiwan J Ophthalmol"},{"key":"3845_CR100","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2147\/TCRM.S303057","volume":"17","author":"HM Teo","year":"2021","unstructured":"Teo HM, Smith TJ, Joseph SS. Efficacy and safety of teprotumumab in thyroid eye disease. Ther Clin Risk Manag. 2021;17:1219\u201330. https:\/\/doi.org\/10.2147\/TCRM.S303057.","journal-title":"Ther Clin Risk Manag"},{"key":"3845_CR101","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/IOP.0000000000002569","volume":"40","author":"AK Terrarosa","year":"2024","unstructured":"Terrarosa AK, DeMaria LN, North VS, Garcia MD, Kim ET, Belinsky I. Menstrual irregularities and amenorrhea in thyroid eye disease patients treated with teprotumumab. Ophthalmic Plast Reconstr Surg. 2024;40:312\u20135. https:\/\/doi.org\/10.1097\/IOP.0000000000002569.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"3845_CR102","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/01676830.2023.2282509","volume":"43","author":"MAJ Ting","year":"2024","unstructured":"Ting MAJ, Topilow NJ, Ediriwickrema LS, Yoon JS, Liu CY, Korn BS, et al. A comparison of proptosis reduction with teprotumumab versus surgical decompression based on fat-to-muscle ratio in thyroid eye disease. Orbit. 2024;43:222\u201330. https:\/\/doi.org\/10.1080\/01676830.2023.2282509.","journal-title":"Orbit"},{"key":"3845_CR103","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/thy.2023.0167","volume":"33","author":"D Toro-Tobon","year":"2023","unstructured":"Toro-Tobon D, Rachmasari KN, Bradley EA, Wagner LH, Tooley AA, Stokken JK, et al. Medical therapy in patients with moderate to severe, steroid-resistant, thyroid eye disease. Thyroid. 2023;33:1237\u201344. https:\/\/doi.org\/10.1089\/thy.2023.0167.","journal-title":"Thyroid"},{"key":"3845_CR104","doi-asserted-by":"publisher","first-page":"e3809","DOI":"10.1097\/GOX.0000000000003809","volume":"9","author":"S Ugradar","year":"2021","unstructured":"Ugradar S, Braun J, Wang Y, Zimmerman E, Douglas RS. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open. 2021;9:e3809 https:\/\/doi.org\/10.1097\/GOX.0000000000003809.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"3845_CR105","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Kang J, Kossler AL, Zimmerman E, Braun J, Harrison AR, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye. 2022;36:1553\u20139. https:\/\/doi.org\/10.1038\/s41433-021-01593-z.","journal-title":"Eye"},{"key":"3845_CR106","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","volume":"35","author":"S Ugradar","year":"2021","unstructured":"Ugradar S, Shi L, Wang Y, Mester T, Yang H, Douglas RS. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye. 2021;35:2607\u201312. https:\/\/doi.org\/10.1038\/s41433-020-01297-w.","journal-title":"Eye"},{"key":"3845_CR107","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1038\/s41433-021-01539-5","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Wang Y, Mester T, Kahaly GJ, Douglas RS. Teprotumumab for thyroid eye disease: early response is not required for benefit. Eye. 2022;36:1403\u20138. https:\/\/doi.org\/10.1038\/s41433-021-01539-5.","journal-title":"Eye"},{"key":"3845_CR108","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1111\/j.1365-2249.2010.04191.x","volume":"161","author":"G Vannucchi","year":"2010","unstructured":"Vannucchi G, Campi I, Bonomi M, Covelli D, Dazzi D, Curr\u00f2 N, et al. Rituximab treatment in patients with active Graves\u2019 orbitopathy: effects on proinflammatory and humoral immune reactions. Clin Exp Immunol. 2010;161:436\u201343. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04191.x.","journal-title":"Clin Exp Immunol"},{"key":"3845_CR109","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","volume":"31","author":"G Vannucchi","year":"2021","unstructured":"Vannucchi G, Campi I, Covelli D, Curr\u00f2 N, Lazzaroni E, Palomba A, et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid. 2021;31:821\u20138. https:\/\/doi.org\/10.1089\/thy.2020.0269.","journal-title":"Thyroid"},{"key":"3845_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101348","volume":"26","author":"KB Vinson","year":"2022","unstructured":"Vinson KB, Kirzhner M. Effects of teprotumumab on patients with long-standing, active thyroid eye disease. Am J Ophthalmol Case Rep. 2022;26:101348. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101348.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"3845_CR111","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12865-024-00613-3","volume":"25","author":"R Wang","year":"2024","unstructured":"Wang R, Song D, Zhong Y, Li H. Potential role of IGF-1R in the interaction between orbital fibroblasts and B lymphocytes: an implication for B lymphocyte depletion in the active inflammatory phase of thyroid-associated ophthalmopathy. BMC Immunol. 2024;25:31 https:\/\/doi.org\/10.1186\/s12865-024-00613-3.","journal-title":"BMC Immunol"},{"key":"3845_CR112","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12020-024-03852-x","volume":"85","author":"XL Wang","year":"2024","unstructured":"Wang XL, Xu SS, Zhou JB, Song ZH. An observational study on the safety of teprotumumab based on FAERS database. Endocrine. 2024;85:313\u201320. https:\/\/doi.org\/10.1007\/s12020-024-03852-x.","journal-title":"Endocrine"},{"key":"3845_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1079852","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Hu H, Chen L, Zhang H, Yang T, Xu X, et al. Observation study of using a small dose of rituximab treatment for thyroid-associated ophthalmopathy in seven Chinese patients: One pilot study. Front Endocrinol. 2023;13:1079852. https:\/\/doi.org\/10.3389\/fendo.2022.1079852.","journal-title":"Front Endocrinol"},{"key":"3845_CR114","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","volume":"60","author":"Y Xin","year":"2021","unstructured":"Xin Y, Xu F, Gao Y, Bhatt N, Chamberlain J, Sile S, et al. Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody, in thyroid eye disease. Clin Pharmacokinet. 2021;60:1029\u201340. https:\/\/doi.org\/10.1007\/s40262-021-01003-3.","journal-title":"Clin Pharmacokinet"},{"key":"3845_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2024.103959","volume":"28","author":"C Zhang","year":"2024","unstructured":"Zhang C, Ersan S, Yousef Y, Sandhur B, Desilets J, McGlone C, et al. The effect of teprotumumab infusion on ocular alignment in patients with symptomatic thyroid eye disease. J AAPOS. 2024;28:103959. https:\/\/doi.org\/10.1016\/j.jaapos.2024.103959.","journal-title":"J AAPOS"},{"key":"3845_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e31932","volume":"10","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Feng X, Guo Y, Kang X, Wang D, Zhang J, et al. Efficacy of rituximab in treating steroid-resistant Graves\u2019 orbitopathy in active moderate-to-severe and sight-threatening forms: a retrospective observation from China. Heliyon. 2024;10:e31932. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31932.","journal-title":"Heliyon"},{"key":"3845_CR117","doi-asserted-by":"publisher","first-page":"e1189","DOI":"10.1111\/aos.15074","volume":"100","author":"H Li","year":"2022","unstructured":"Li H, Yang L, Song Y, Zhao X, Sun C, Zhang L, et al. Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves\u2019 orbitopathy: a systematic review and network meta-analysis. Acta Ophthalmol. 2022;100:e1189\u201398. https:\/\/doi.org\/10.1111\/aos.15074.","journal-title":"Acta Ophthalmol"},{"key":"3845_CR118","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/rmdopen-2015-000213","volume":"2","author":"A Rubbert-Roth","year":"2016","unstructured":"Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B, Pulley J, et al. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab. RMD Open. 2016;2:e000213 https:\/\/doi.org\/10.1136\/rmdopen-2015-000213.","journal-title":"RMD Open"},{"key":"3845_CR119","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/rheumatology\/keae140","volume":"64","author":"R Westermann","year":"2025","unstructured":"Westermann R, Cordtz RL, Duch K, Mellemkjaer L, Hetland ML, Magnussen B, et al. Cancer risk with tocilizumab\/sarilumab, abatacept and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study. Rheumatology. 2025;64:1019\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keae140.","journal-title":"Rheumatology"},{"key":"3845_CR120","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13075-017-1482-y","volume":"19","author":"SK Cho","year":"2017","unstructured":"Cho SK, Lee J, Han M, Bae SC, Sung YK. The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs. Arthritis Res Ther. 2017;19:277 https:\/\/doi.org\/10.1186\/s13075-017-1482-y.","journal-title":"Arthritis Res Ther"},{"key":"3845_CR121","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/WNO.0000000000002066","volume":"44","author":"JB Davis","year":"2024","unstructured":"Davis JB, Mudalegundi S, Henderson AD, Carey AR. Stability of Ocular Alignment After Teprotumumab Therapy in a Cohort of Patients With Thyroid Eye Disease and Baseline Diplopia. J Neuroophthalmol. 2024;44:527\u2013532 https:\/\/doi.org\/10.1097\/WNO.0000000000002066.","journal-title":"J Neuroophthalmol."},{"key":"3845_CR122","doi-asserted-by":"crossref","unstructured":"Jos\u00e9 JC, Rivera-Moscoso R, Jorge AF, Vargas-S\u00e1nchez J, Ortega-Guti\u00e9rrez G, Madriz-Prado R, et al. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. InAnnales d\u2019Endocrinologie Vol. 81, pp. 78\u201382. Elsevier Masson, 2020.","DOI":"10.1016\/j.ando.2020.01.003"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03845-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03845-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:14:45Z","timestamp":1754925285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03845-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":122,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3845"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03845-8","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In table 1 the citations 93, 94, 95, 96, 104, 105, 106 and 107 have been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}